亞盛醫藥
Ascentage Pharma

ASCENTAGE PHARMA GROUP INTERNATIONAL
亞盛醫藥集團
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 6855)

Voluntary Announcement

Ascentage Pharma Accepted for the Third Time to Release Updated Clinical Data of HQP1351 (Olverembatinib) in Drug-Resistant Chronic Myeloid Leukemia in an Oral Presentation at the American Society of Hematology Annual Meeting

Ascentage Pharma Group International (the "**Company**" or "**Ascentage Pharma**") is pleased to announce that the results from two pivotal Phase II clinical studies of the novel Class I new drug BCR-ABL inhibitor created by the Company, HQP1351 (the determined English common name: Olverembatinib), have been accepted for oral presentation at the 62nd American Society of Hematology (ASH) Annual Meeting. Qian Jiang, M.D., who will be making the presentation during the meeting, and Xiaojun Huang, M.D., from the Hematology Department of Peking University People's Hospital, are the principal investigators of these studies. Following 2018 and 2019, this will be the third time that the updated clinical data of HQP1351 has been accepted for oral presentation at the ASH Annual Meeting. Being accepted for three consecutive years signifies the recognition of HQP1351's safety and efficacy profiles by the international hematology community.

HQP1351 is a novel Class I drug under the research of Ascentage Pharma, being a novel third generation tyrosine kinase inhibitor (TKI) for the treatment of patients with chronic myeloid leukemia (CML) resistant to first-and second-generation TKIs. The updated clinical data that has been accepted for oral presentation is from the two pivotal Phase II clinical trials of HQP1351 in TKI-resistant patients with T315I-mutant CML. As of March 23, 2020, the pivotal Phase II HQP1351-CC201 clinical trial enrolled a total of 41 patients with CML in the chronic phase (CML-CP); and as of February 11, 2020, the pivotal Phase II HQP1351-CC202 clinical trial enrolled a total of 23 patients with CML in the accelerated phase (CML-AP). Results from those two trials have shown favorable efficacy and tolerability of HQP1351 in TKI-resistant patients with T315I-mutant CML-CP and CML-AP.

Based on the results from these two pivotal Phase II clinical trials, Ascentage Pharma submitted a New Drug Application (NDA) for HQP1351 for the treatment of patients with T315I-mutant CML-CP and CML-AP in China this year. The NDA has been subsequently granted Priority Review status.

Cautionary Statement required by Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: We cannot guarantee that we will be able to obtain further approval for, or ultimately market, HQP1351 successfully.

By order of the Board
Ascentage Pharma Group International
Dr. Yang Dajun
Chairman and Executive Director

Suzhou, People's Republic of China, November 9, 2020

As at the date of this announcement, the Board of Directors of the Company comprises Dr. Yang Dajun as Chairman and executive Director, Dr. Wang Shaomeng, Dr. Tian Yuan, Mr. Zhao Qun, Dr. Lu Simon Dazhong and Mr. Liu Qian as non-executive Directors, and Mr. Ye Changqing, Dr. Yin Zheng and Mr. Ren Wei as independent non-executive Directors.